Automating Cell Therapy Manufacturing And Enabling Rapid Multi-Site Tech Transfer

For patients with life-threatening diseases, cell and gene therapies can be life-saving. Yet, the manual manufacturing processes for these therapies are often a bottleneck, limiting their availability and contributing to high costs. The Cell Therapy Manufacturing Center (CTMC) and Ori Biotech collaborated to evaluate how an automated manufacturing platform could improve CAR-T cell therapy production.

A three-phase study demonstrated that the new automated platform could deliver on all fronts, and even led to a 127% increase in CAR-T cell yield in one run. The team also proved that the optimized process could be successfully transferred to a second manufacturing site in less than two weeks, with the data supporting regulatory comparability.

The case study details how these advancements prove that automated manufacturing can help improve a product's commercial viability while reducing time, cost, and complexity.